58492-77-6

Usage

Uses

Used in Pharmaceutical Industry:
(5-(4-Methoxyphenyl)isoxazol-3-yl)methanol is used as a potential pharmaceutical agent for its structural features that may contribute to the development of new drugs. The isoxazole moiety, found in some bioactive molecules, suggests that (5-(4-Methoxyphenyl)isoxazol-3-yl)methanol could be involved in the treatment of various diseases or conditions.
Used in Chemical Synthesis:
(5-(4-Methoxyphenyl)isoxazol-3-yl)methanol is used as a versatile building block in chemical synthesis due to its solubility and reactivity. The presence of the methanol group allows for further chemical modifications and the creation of a range of derivative compounds with potential applications in various fields.

Upstream product

• 3319-15-1 rac-1-(4-methoxyphenyl)-ethanol 
• 39757-31-8 methyl (4-methoxybenzoyl)pyruvate 
• 123-11-5 4-methoxy-benzaldehyde 
• 425609-97-8 methyl 5-(4-methoxyphenyl)isoxazole-3-carboxylate 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 35322-20-4 ethyl 3-(4-methoxybenzoyl)pyruvate 
• 925006-96-8 ethyl 5-(4-methoxyphenyl)isoxazole-3-carboxylate 

Downstream Products

• 934603-49-3 3-(bromomethyl)-5-(4-methoxyphenyl)isoxazole 
• 1277100-09-0 C₂₃H₂₅N₃O₄*ClH 
• 1277100-17-0 C₂₄H₂₇N₅O₄*ClH 
• 1378938-23-8 2-amino-3-cyano-7-dimethylamino-4-(5-(4-methoxyphenyl)isoxazol-3-yl)-4H-chromene 
• 870703-95-0 C₁₁H₉NO₃ 

Relevant academic research and scientific papers

Novel N-Substituted oseltamivir derivatives as potent influenza neuraminidase inhibitors: Design, synthesis, biological evaluation, ADME prediction and molecular docking studies

The discovery of novel potent neuraminidase (NA) inhibitors remains an attractive approach for treating infectious diseases caused by influenza. In this study, we describe the design and synthesis of novel N-substituted oseltamivir derivatives for probing the 150-cavity which is nascent to the activity site of NA. NA inhibitory studies showed that new derivatives demonstrated the inhibitory activity with IC50 values at nM level against NA of a clinical influenza virus strain. Moreover, the in silico ADME predictions showed that the selected compounds had comparable properties with oseltamivir carboxylate, which demonstrated the druggablity of these derivatives. Furthermore, molecular docking studies showed that the most potent compound 6f and 10i could adopt different modes of binding interaction with NA, which may provide novel solutions for treating oseltamivir-resistant influenza. Based on the research results, we consider that compounds 6f and 10i have the potential for further studies as novel antiviral agents.

Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators

Antibiotic resistance among clinically significant bacterial pathogens is becoming a prevalent threat to public health, and new antibacterial agents with novel mechanisms of action hence are in an urgent need. Utilizing computational docking method and structure-based optimization strategy, we rationally designed and synthesized two series of isoxazol-3-yl- and isoxazol-5-yl-containing benzamide derivatives that targeted the bacterial cell division protein FtsZ. Evaluation of their activity against a panel of Gram-positive and -negative pathogens revealed that compounds B14 and B16 that possessed the isoxazol-5-yl group showed strong antibacterial activity against various testing strains, including methicillin-resistant Staphylococcus aureus and penicillin-resistant S. aureus. Further molecular biological studies and docking analyses proved that the compound functioned as an effective inhibitor to alter the dynamics of FtsZ self-polymerization via a stimulatory mechanism, which finally terminated the cell division and caused cell death. Taken together, these results could suggest a promising chemotype for development of new FtsZ-targeting bactericidal agent.

Novel hybrid molecules of isoxazole chalcone derivatives: Synthesis and study of In Vitro cytotoxic activities

Background: Now-a-days, the model of “hybrid drugs” has acquired recognition in medicine due to their significant role in the treatment of different health problems. Methods: We have synthesized new series of isoxazole-chalcone conjugates (14a-m) by the C

Design, synthesis and biological evaluation of stilbene derivatives as novel inhibitors of protein tyrosine phosphatase 1B

By imitating the scaffold of lithocholic acid (LCA), a natural steroidal compound displaying Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, a series of stilbene derivatives containing phenyl-substituted isoxazoles were designed and synthesized. The structures of the title compounds were confirmed by 1H-NMR, 13C-NMR and HRMS. Activities of the title compounds were evaluated on PTP1B and the homologous enzyme TCPTP by using a colorimetric assay. Most of the target compounds had good activities against PTP1B. Among them, compound 29 (IC50 = 0.91 ± 0.33 μM), characterized by a 5-(2,3-dichlorophenyl) isoxazole moiety, exhibited an activity about 14-fold higher than the lead compound LCA and a 4.2-fold selectivity over TCPTP. Compound 29 was identified as a competitive inhibitor of PTP1B with a Ki value of 0.78 μM in enzyme kinetic studies.

2-Amino-3-cyano-4-(5-arylisoxazol-3-yl)-4H-chromenes: Synthesis and in vitro cytotoxic activity

A new series of 4-aryl-4H-chromenes bearing a 5-arylisoxazol-3-yl moiety at the C-4 position were prepared as potential anticancer agents. The in vitro cytotoxic activity of the synthesized compounds was investigated against a panel of tumor cell lines in

Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa

New chloro-substituted biarylmethoxyphenyl piperidine-4-carboxamides were synthesized and assayed in vitro as inhibitors of the blood coagulation enzymes factor Xa (fXa) and thrombin. An investigation of effects of the amidine and isopropyl groups attache

NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND

The present invention provides a compound having excellent regulating action on blood lipid level. The present invention provides a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, etc., wherein A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R1 represents COOH or the like; each R2 represents an alkyl or the like; each R3 represents an optionally substituted phenyl, an optionally substituted phenylalkyl, or the like; m represents 0, 1, 2, or 3; n represents 0 or 1; each of R4, R5, R6, and R7 represents H, an alkyl, or the like; and B represents an optionally substituted naphthyl, an optionally substituted aromatic heterocyclyl, or a group represented by the following formula (II) wherein each of B1 and B2 represents an optionally substituted phenyl or an optionally substituted aromatic heterocyclyl.